Diverse pro-inflammatory mediators, such as interleukins (IL1 and IL6), tumor necrosis factor (TNF)α, and C-reactive protein (CRP), are increased in CKD patients and participate in the atherogenic process [8,9]. This evidence concerns the gene IL6 and chronic kidney disease.